Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lobo

Showing results (21-30 of 1,050) with videos related to

Pageof 105
Sort By:
Menopause (New York, N.Y.)|December 24, 2015
Is there a relationship between cardiovascular risk factors and hysterectomy?Rogerio A Lobo
Best Practice & Research. Clinical Obstetrics & Gynaecology|July 9, 2002
Menopausal medicineR A Lobo
Menopause (New York, N.Y.)|August 28, 2020
What drives metabolic syndrome after menopause, and can we do anything about it?Roger A Lobo
American Journal of Obstetrics and Gynecology|June 1, 1988
Lipids, clotting factors, and diabetes: endogenous risk factors for cardiovascular diseaseR A Lobo
Obstetrics and Gynecology|April 1, 1990
Cardiovascular implications of estrogen replacement therapyR A Lobo
American Journal of Obstetrics and Gynecology|September 1, 1995
Estrogen replacement: the evolving role of alternative delivery systems. IntroductionR A Lobo
American Journal of Obstetrics and Gynecology|September 1, 1995
Benefits and risks of estrogen replacement therapyR A Lobo
Endocrine|November 16, 2004
The rationale for low-dose hormonal therapyRogerio A Lobo
Endocrinology and Metabolism Clinics of North America|December 1, 1988
The role of neurotransmitters and opioids in polycystic ovarian syndromeR A Lobo
International Journal of Fertility|January 1, 1988
The androgenicity of progestational agentsR A Lobo
Pageof 105

Showing results (21-30 of 1,050) with videos related to

Sort By:
Pageof 105
Menopause (New York, N.Y.)|December 24, 2015
Is there a relationship between cardiovascular risk factors and hysterectomy?Rogerio A Lobo
Best Practice & Research. Clinical Obstetrics & Gynaecology|July 9, 2002
Menopausal medicineR A Lobo
Menopause (New York, N.Y.)|August 28, 2020
What drives metabolic syndrome after menopause, and can we do anything about it?Roger A Lobo
American Journal of Obstetrics and Gynecology|June 1, 1988
Lipids, clotting factors, and diabetes: endogenous risk factors for cardiovascular diseaseR A Lobo
Obstetrics and Gynecology|April 1, 1990
Cardiovascular implications of estrogen replacement therapyR A Lobo
American Journal of Obstetrics and Gynecology|September 1, 1995
Estrogen replacement: the evolving role of alternative delivery systems. IntroductionR A Lobo
American Journal of Obstetrics and Gynecology|September 1, 1995
Benefits and risks of estrogen replacement therapyR A Lobo
Endocrine|November 16, 2004
The rationale for low-dose hormonal therapyRogerio A Lobo
Endocrinology and Metabolism Clinics of North America|December 1, 1988
The role of neurotransmitters and opioids in polycystic ovarian syndromeR A Lobo
International Journal of Fertility|January 1, 1988
The androgenicity of progestational agentsR A Lobo
Pageof 105